Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Jairia Dela Cruz, 5 days ago
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Stephen Padilla, 4 days ago
Circulating miR-155 may be potentially used as a diagnostic and therapeutic monitoring marker in breast cancer, suggests an Indonesian study presented at the 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).
Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).

Afatinib followed by osimertinib in EGFR+ T790M NSCLC extends chemo-free time

Pearl Toh
03 Dec 2018
Dr Ross Soo

Sequential treatment with afatinib followed by osimertinib enables prolonged chemotherapy-free treatment while sustaining clinical benefit in patients with EGFR-mutation positive (EGFR+) non-small–cell lung cancer (NSCLC) who acquire T790M mutation, according to the real-world retrospective GioTag study presented at ESMO Asia 2018.

“Regardless of which first-line TKI* is chosen, acquired resistance is inevitable. Emergence of the T790M mutation is the main molecular resistance mechanism to gefitinib, erlotinib, and afatinib, and is found in about 50–70 percent of tumours at the time of acquired resistance,” explained Dr Ross Soo of the National University Hospital, Singapore. “Treatment with sequential EGFR TKIs, with osimertinib reserved as a second-line option, may therefore maximize time on targeted drugs.”

The multinational observational study analysed data retrospectively collected from 204 patients (median 60 years, 53.9 percent female) with EGFR+ (of which 73.5 percent were Del19 and 26 percent were L858R mutations) NSCLC who acquired T790M after afatinib therapy. About one quarter of the patients (24.5 percent) were Asians. [ESMO Asia 2018, abstract LBA7]

The primary endpoint of time on treatment (ToT), defined as duration from afatinib initiation to osimertinib discontinuation, was an overall median of 27.6 months (90 percent confidence interval [CI], 25.9–31.3). When the treatment was analysed individually, the patients received afatinib for a median of 11.9 months (90 percent CI, 10.9–12.2) and osimertinib for a median of 14.3 months (90 percent CI, 12.8–15.9). The main reason for osimertinib discontinuation was progressive disease (n=98), followed by deaths (n=4) and adverse events (n=2).

Landmark analysis showed that the OS rate was 79 percent at 2 years and 69 percent at 2.5 years. The 2-year OS rate was particularly higher, at 83.9 percent in the patient subgroup with ECOG PS 0/1.

Calling these an “encouraging results”, Soo said “Sequential afatinib and osimertinib provided sustained clinical benefit in real-world clinical practice.”  

In general, clinical benefit in terms of ToT was consistent across subgroups. Patients with poor prognosis, including those with stable brain metastases (median, 19.4 months) and ECOG performance status (PS) ≥2 (median, 22.2 months) also appeared to benefit.

Specifically, median ToT was longer in the patient subgroup with Del19 EGFR vs those with L858R mutation (median, 30.3 vs 19.1 months). In particular, ToT was further prolonged in Del19 patients who also had ECOG PS 0/1 (median, 36.4 months, 90 percent CI, 29.2–46.7).

Noting that approximately 75 percent of the patients were Del19-positive, Soo said this likely reflects the higher frequency of T790M acquired resistance in Del19-positive vs L858R-positive tumours.  

Asian patients also derived a greater benefit than non-Asians (median ToT, 46.7 vs 27.6 months).

“With a median ToT of 27.6 months in real-world setting, notably prolonged in Asian patients and those with Del19-positive disease, sequential therapy appears feasible and potentially effective,” said Soo.

“While prospective studies are needed to fully determine the optimum treatment strategy, this sequential approach might offer sustained clinical benefit, while avoiding chemotherapy,” he added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Jairia Dela Cruz, 5 days ago
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Stephen Padilla, 4 days ago
Circulating miR-155 may be potentially used as a diagnostic and therapeutic monitoring marker in breast cancer, suggests an Indonesian study presented at the 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).
Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).